OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the enhanced performance CPSI’s next generation supercritical nitrogen (SCN) cryoablation device and its potential application in the treatment of cardiac arrhythmias. The study, titled “Evaluation of a New Epicardial Cryoablation System for the Treatment of Cardiac Tachyarrhythmias”, published as an open access article in the journal Trends in Medicine (February 2, 2018, accessible free of charge at: http://www.oatext.com/evaluation-of-a-new-epicardial-cryoablation-system-for-the-treatment-of-cardiac-tachyarrhythmias.php), was a multi-institutional collaboration between researchers from CPSI and Binghamton University.
The article details developments in CPSI’s cardiac cryoablation technology platform. The study investigated the performance of the patented Supercritical Nitrogen (SCN) cryoablation system and epicardial cryoablation probe developed by CPSI. The studies, conducted using a series of heat loaded engineering and tissue models, demonstrated the ability of the system to quickly and effectively deliver an ablative dose. Commenting on the study, Dr. John M. Baust (CPSI President and Lead Scientist) stated “We have been working on a series of a next generation cryoablation devices and probes for targeting various cardiac arrhythmias for a number of years. These activities have resulted in the development of a platform of new ablation probes and catheters, the ICEolate platform, designed to support ablation of cardiac tissue using either a epicardial or endocardial approach. This specific study focused on evaluations of the epicardial cryoprobe technology. The results demonstrate that the SCN system is able to generate ablative power several fold greater than today’s commercial cryoablation systems and as such deliver a ablative dose in less than one minute in many cases.”
This study was conducted as part of CPSI’s ongoing research and technology development program which involves the development of a next generation cryoablation devices and approaches for the treatment of various disease states. Ongoing efforts continue to build upon this success and are focusing on continued development, optimization and testing of these new devices. Speaking to the broader device development program at CPSI, Baust added “while this study focused on our prototype epicardial cardiac probe, we are also actively developing linear and balloon tipped catheter technologies as part of the ICEolate platform to support endocardial based procedures. The power of the patented cryoablation engines that CPSI’s engineers have developed has opened a number of doors for advanced treatment for various diseases. We are excited to take the next steps with this technology.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”
Click Here to read the full Press Release: New Cryoablation Device Targets Enhanced Treatment of Cardiac Arrhythmias
View other CPSI Biotech news and recent patent announcements
OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the potential benefit of the combination of calcitriol pre-treatment and freezing (cryoablation) for targeting prostate cancer. The study, titled Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model, published in the open access journal Cancer Control January-March 2018 edition (http://journals.sagepub.com/doi/full/10.1177/1073274818757418) was a multi-institutional collaboration between researchers from CPSI and Binghamton University.
The article details the impact of exposing prostate cancer cells to a gradually increasing dose of calcitriol over a one month period and then exposing cells to mild sub-freezing temperatures associated with a cryoablative procedure. The study investigated the impact of the application of a gradual calcitriol dose escalation regime in comparison to a single (1 day) high dose exposure regime as well as freezing alone in an in vitro prostate cancer cell model. The data show that exposing cancer cells to calcitriol in combination with mild freezing resulted in increased cell death compared to either treatment alone. Further, the data demonstrated that gradual dose escalation of calcitriol yielded a similar outcome as acute high dose exposure. Commenting on the study, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “cryoablation is a very effective treatment modality used widely to treat various cancers. One limitation of Cryo is that different cancer cells (stages and types) have been shown to have differing tolerances to mild freezing temperatures associated with the outer edge of the frozen mass. In addition to developing advanced cryoablative devices, one of our foci at CPSI is to identify new combinatorial strategies to increase cancer destruction at these mild sub-freezing temperatures. This study demonstrates that the combination of calcitriol and freezing can yield prostate cancer destruction at temperatures as warm as -15°C, whereas typically temperatures of -40°C or colder are necessary for complete destruction.” Dr. Kimberly Santucci (CPSI Research Scientist and the study’s first author) stated “the anticancer properties of VD3 metabolites, including calcitriol, have been extensively studied and we previously reported on the benefits of the combination of calcitriol and freezing. While beneficial, previous studies focused on the acute administration and short term exposure of high dose calcitriol. Clinical translation of that approach would require multiple surgical procedures over several days. The objective of this study was to model the gradual increase of calcitriol concentration such as might be obtained via a one month oral dosing regimen. Our findings suggest that the application of gradual dose escalation results in similar sensitization of cancer cells to freezing as an acute high dose regime.”
Ongoing efforts at CPSI continue to build upon this success and are focusing on further development, optimization and testing of new minimally invasive surgical devices designed to treat cancers including prostate, pancreatic, bladder, kidney, esophageal and breast cancer among others. Speaking to the broader device development program at CPSI, Dr Baust noted “an ongoing Phase II SBIR award from NCI has provided CPSI the opportunity to ramp up our R&D studies around our advanced cryoablation device platform in combination with vitamin D3 metabolite pre-treatment for the treatment of liver and pancreatic cancers. This project incorporates several of CPSI’s patented technologies, including our cryoengines, thermal ablation probes and catheters and adjunctive anticancer agents (SensitICERs). With success, these efforts will provide an advanced minimally invasive approach for treating various cancers.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”
More information on the CPSI’s cryoablation and SensitICER technologies can be found on CPSI’s website at www.CPSIBiotech.com/technologies. The full press release can be accessed here.
OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the potential benefit of the combination of heat (hyperthermia) and freezing (cryoablation) based ablation strategies for the targeting of pancreatic cancer. The study, titled Dual Thermal Ablation of Pancreatic Cancer Cells as an Improved Combinatorial Treatment Strategy, published as an open access article in the journal Liver and Pancreatic Sciences, was a multi-institutional collaboration between researchers from CPSI and Binghamton University.
The article details the impact of treating pancreatic cancer cells using two ablative strategies, cryo and hyperthermic ablation, used clinically to treat pancreatic as well as other cancers. One arm of the study investigated the impact of the combined application of these ablative treatments strategies on pancreatic cancer in an in vitro cell model. The data show that the combination of exposing cancer cells to heat based ablation followed by freezing results in increased cell death compared to when either is applied as a single exposure (mono) therapy. Commenting on the article, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “this study demonstrates that ablative therapies provide for an effective means of destroying pancreatic cancer cells. These initial findings from this in vitro suggest that further investigation into the use of a dual thermal ablation regime for treating pancreatic cancer is warranted.”
This study was conducted as part of CPSI’s ongoing research and technology development program focused on the development of a next generation cryoablation device (FrostBite™) and approach for the treatment of pancreatic cancer. The initial development efforts behind FrostBite™ and the DTA study have been supported, in part, by a Phase I and II SBIR grant awarded to CPSI by the National Cancer Institute. Ongoing efforts at CPSI continue to build upon this success and are focusing on further development, optimization and testing of FrostBite™ for the treatment of pancreatic cancer as well as other gastroenterological (GI) based cancers. With development underway, CPSI is poised to embark down the commercialization path. To this end, Dr. John M. Baust commented “We are actively seeking investors and partners to join our team to bring this potentially lifesaving technology platform to the market.” To enable this, a start-up company (GI Cryo, Inc.) has been formed focused in the GI area to commercialize FrostBite™ and other related technologies.
The open access article, initially published online November 30th , is timely in view of the recent increased interest in use of cryoablation for the treatment of cancer and can be accessed free of charge via the Liver and Pancreatic Science website at http://www.oatext.com/Dual-thermal-ablation-of-pancreatic-cancer-cells-as-an-improved-combinatorial-treatment-strategy.php#Article.
Click Here to read the full Press Release: Combinatorial Ablative Strategies Yield Improved Destruction of Pancreatic Cancer Cells
More information on FrostBite™ or any of CPSI’s other technologies is available on CPSI Biotech’s website www.cpsibiotech.com.